olmesartan has been researched along with Left Ventricular Hypertrophy in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aichner, S; Albrecht, D; Bremerich, J; Delles, C; Freyhardt, P; Heye, T; Hrabak-Paar, M; Janka, R; Keicher, C; Khder, Y; Langenickel, T; Mayr, M; Ott, C; Schmieder, RE; Wagner, F; Yates, D | 1 |
| Saito, Y; Takami, T | 2 |
| Halleck, F; Holleck-Weithmann, S; Kossmehl, P; Kreutz, R; Rothermund, L; Schröder, K | 1 |
| Ding, Z; Ge, J; Gong, H; Jiang, G; Li, Y; Wang, S; Wang, X; Wu, J; Ye, Y; Yin, P; Yuan, J; Zhang, W; Zhou, J; Zou, Y | 1 |
| Arimoto, M; Hata, H; Osaka, S; Sakino, H; Sezai, A; Shiono, M; Yaoita, H | 1 |
| Azuma, K; Horiuchi, M; Kimura, K; Masuda, S; Matsuda, M; Mogi, M; Ozawa, M; Shigenaga, A; Tamura, K; Tsurumi-Ikeya, Y; Uchino, K; Umemura, S; Wakui, H | 1 |
| Inagaki, K; Mochly-Rosen, D; Palaniyandi, SS | 1 |
| Chavanu, KJ; Dubiel, R; Rosendorff, C; Xu, J | 1 |
| Futai, R; Ito, T; Kawanishi, Y; Kitaura, Y; Terasaki, F | 1 |
| Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T | 1 |
| Dellsperger, KC; DeMarco, VG; Gul, R; Habibi, J; Hayden, MR; Johnson, MS; Pulakat, L; Sowers, JR; Tilmon, RD; Whaley-Connell, AT; Winer, N | 1 |
| Hata, M; Sezai, A; Shiono, M; Soma, M; Unosawa, S; Wakui, S; Yoshitake, I | 1 |
| Chuang, YC; Fang, KM; Su, YK; Wu, MS | 1 |
| Ge, J; Guo, J; Jiang, G; Li, L; Wang, S; Wu, J; You, J; Zou, Y | 1 |
| Chang, NC; Chou, TF; Lee, TM; Lin, MS | 1 |
| Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishio, M; Ohtani, T; Sakata, Y; Takeda, Y; Yamamoto, K; Yoshida, J | 1 |
| Hayashi, T; Kitaura, Y; Kwak, CJ; Matsumura, Y; Mori, T; Nakano, D; Okada, Y; Sohmiya, K; Tazawa, N; Yamashita, C | 1 |
8 trial(s) available for olmesartan and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Aorta; Aorta, Thoracic; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Essential Hypertension; Female; Heart Failure; Humans; Hypertrophy, Left Ventricular; Imidazoles; Magnetic Resonance Angiography; Male; Medication Adherence; Middle Aged; Neprilysin; Tetrazoles; Valsartan; Vascular Stiffness; Ventricular Remodeling | 2017 |
Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial.
Topics: Aged; Amlodipine; Azetidinecarboxylic Acid; Diastole; Dihydropyridines; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Male; Middle Aged; Pulse Wave Analysis; Tetrazoles; Vascular Stiffness; Ventricular Function, Left | 2013 |
Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Blood Pressure; Cardiac Surgical Procedures; Drug Substitution; Essential Hypertension; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Japan; Male; Middle Aged; Oxadiazoles; Prospective Studies; Renin; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome; Ventricular Remodeling | 2016 |
Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome | 2009 |
Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Echocardiography, Doppler, Color; Female; Fibrosis; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Inflammation; Male; Middle Aged; Myocardium; Severity of Illness Index; Tetrazoles; Time Factors; Treatment Outcome; Ventricular Function, Left | 2009 |
Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Male; Middle Aged; Natriuretic Peptide, Brain; Peptidyl-Dipeptidase A; Tetrazoles | 2010 |
Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Chi-Square Distribution; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Japan; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography | 2011 |
Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.
Topics: Aged; Aldosterone; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Benzimidazoles; Biphenyl Compounds; Cardiac Surgical Procedures; Compliance; Drug Substitution; Female; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Japan; Male; Middle Aged; Prospective Studies; Renin; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome | 2011 |
10 other study(ies) available for olmesartan and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Cardiorenal protection in experimental hypertension with renal failure: comparison between vasopeptidase inhibition and angiotensin receptor blockade.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Rats, Wistar; Receptors, Angiotensin; Renal Insufficiency; Tetrazoles | 2015 |
Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Apoptosis; Autophagy; Blood Pressure; Captopril; Chronic Disease; Disease Models, Animal; Drug Therapy, Combination; Drugs, Chinese Herbal; Gene Expression Regulation; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Male; Metoprolol; Mice, Inbred C57BL; Myocytes, Cardiac; Signal Transduction; Tetrazoles; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Effect of olmesartan on tissue expression balance between angiotensin II receptor and its inhibitory binding molecule.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blotting, Western; Disease Models, Animal; Gene Expression; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Ventricular Remodeling | 2008 |
Mast cells and epsilonPKC: a role in cardiac remodeling in hypertension-induced heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Degranulation; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Male; Mast Cells; Protein Kinase C-delta; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Rats; Rats, Inbred Dahl; Signal Transduction; Tetrazoles; Time Factors | 2008 |
Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Body Weight; Heart; Heart Function Tests; Hypertrophy, Left Ventricular; Imidazoles; Janus Kinase 2; Male; Myocardium; Myocytes, Cardiac; Oxidative Stress; Phosphorylation; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Renin-Angiotensin System; Telemetry; Telmisartan; Tetrazoles | 2011 |
Effects of olmesartan on arterial stiffness in rats with chronic renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Aorta; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Glycation End Products, Advanced; Hemodynamics; Hypertrophy, Left Ventricular; Imidazoles; Kidney Failure, Chronic; Male; Malondialdehyde; Nephrectomy; Oxidative Stress; Rats; Rats, Wistar; Reactive Oxygen Species; Tetrazoles; Vascular Stiffness | 2012 |
Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium-Binding Proteins; Dipeptides; Disease Models, Animal; Fibrosis; Hypertrophy, Left Ventricular; Imidazoles; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Microcirculation; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Receptor, Notch1; Tetrazoles; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Remodeling | 2013 |
Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin-1; Gene Expression Regulation; Heart Ventricles; Hemodynamics; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Imidazoles; Male; Myocardial Infarction; Pravastatin; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Ventricular Remodeling | 2006 |
Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chemokine CCL2; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Inflammation; Male; NADPH Oxidases; Oxidative Stress; Random Allocation; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Tetrazoles; Transforming Growth Factor beta1; Ventricular Remodeling | 2007 |
Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice.
Topics: Aldehydes; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Heart Ventricles; Hypertrophy, Left Ventricular; Hypoxia; Imidazoles; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Knockout; Myocytes, Cardiac; NADPH Oxidases; NF-kappa B; Oxidative Stress; Superoxides; Tetrazoles; Ventricular Remodeling | 2007 |